Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Glioblastoma 2Choriocarcinoma 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Trophoblastic Tumor, Placental Site 1Ovarian Neoplasms 1Liver Neoplasms 1Glioma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 6Specimen Handling 4Cisplatin 4pembrolizumab 3enfortumab vedotin 3atezolizumab 3Nivolumab 3Magnetic Resonance Spectroscopy 3Carboplatin 3vinflunine 2eribulin 2avelumab 2Standard of Care 2Biopsy 2vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1relatlimab 1pegfilgrastim 1merphos 1guadecitabine 1genexol-PM 1dehydroftorafur 1carotuximab 1Vitamin D 1Vinblastine 1Ramucirumab 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ureteral Neoplasms × carotuximab × Clear all
NCT01328574 2017-01-13

TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
13 enrolled 15 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡